Literature DB >> 17499921

Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats.

M B Pereira1, R L M Freitas, M A G Assis, R F Silva, M M F Fonteles, R M Freitas, R N Takahashi.   

Abstract

This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats. Glutamate (10 and 20 mg/kg), N-methyl-d-aspartate (NMDA, 5 and 10 mg/kg), ketamine (1.5 and 2.0 mg/kg), gabapentin (200 and 250 mg/kg), phenobarbital (50 and 100 mg/kg) and vigabatrin (250 and 500 mg/kg) were administered intraperitoneally, 30 min prior to pilocarpine (400 mg/kg, i.p.). The animals were observed (24 h) to determine: number of peripheral cholinergic signs, tremors, stereotyped movements, seizures, SE, latency to first seizure and number of deaths after pilocarpine treatment. NMDA and glutamate had pro-convulsive effects in both doses tested. Smaller and higher doses of these drugs no protected and increased pilocarpine-induced seizures and/or mortality. Gabapentin, vigabatrin, phenobarbital and ketamine protected against seizures and increased the latency to first seizure. Thus, these results suggest that caution should be taken in the selection of pharmacotherapy and dosages for patients with seizures and SE because of the possibility of facility the convulsive process toxicity, SE and the mortality of adult animals in this seizures model that is similar temporal lobo epilepsy in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499921     DOI: 10.1016/j.neulet.2007.04.021

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Behavioral and genotoxic evaluation of rosmarinic and caffeic acid in acute seizure models induced by pentylenetetrazole and pilocarpine in mice.

Authors:  Vanessa Rodrigues Coelho; Caroline Gonçalves Vieira; Luana Pereira de Souza; Lucas Lima da Silva; Pricila Pflüger; Gabriela Gregory Regner; Débora Kuck Mausolff Papke; Jaqueline Nascimento Picada; Patrícia Pereira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-30       Impact factor: 3.000

2.  DNA damage and oxidative stress induced by seizures are decreased by anticonvulsant and neuroprotective effects of lobeline, a candidate to treat alcoholism.

Authors:  Liana Dantas da Costa E Silva; Patrícia Pereira; Gabriela Gregory Regner; Fernanda Brião Menezes Boaretto; Cleonice Hoffmann; Pricila Pflüger; Lucas Lima da Silva; Luiza Reinhardt Steffens; Ana Moira Morás; Dinara Jaqueline Moura; Jaqueline Nascimento Picada
Journal:  Metab Brain Dis       Date:  2017-10-14       Impact factor: 3.584

3.  Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.

Authors:  Xiao-Qing Peng; Xia Li; Jie Li; P Veeraraghavan Ramachandran; Pravin D Gagare; Debarshi Pratihar; Charles R Ashby; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drug Alcohol Depend       Date:  2007-12-11       Impact factor: 4.492

Review 4.  Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus.

Authors:  F A Zeiler
Journal:  Crit Care Res Pract       Date:  2015-01-12

5.  First-line medication dosing in pediatric refractory status epilepticus.

Authors:  Alejandra Vasquez; Marina Gaínza-Lein; Nicholas S Abend; Marta Amengual-Gual; Anne Anderson; Ravindra Arya; J Nicholas Brenton; Jessica L Carpenter; Kevin Chapman; Justice Clark; Raquel Farias-Moeller; William D Gaillard; Tracy Glauser; Joshua L Goldstein; Howard P Goodkin; Rejean M Guerriero; Kush Kapur; Yi-Chen Lai; Tiffani L McDonough; Mohamad A Mikati; Lindsey A Morgan; Edward J Novotny; Adam P Ostendorf; Eric T Payne; Katrina Peariso; Juan Piantino; James J Riviello; Kumar Sannagowdara; Robert C Tasker; Dmitry Tchapyjnikov; Alexis Topjian; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Tobias Loddenkemper
Journal:  Neurology       Date:  2020-09-10       Impact factor: 9.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.